{
  "timestamp": "2025-12-23T03:22:37.074250",
  "agent_type": "medication_analyzer",
  "medication_name": "paracetamol",
  "drug_class": "Non-opioid analgesic and antipyretic (p-aminophenol derivative)",
  "mechanism_of_action": "Exact mechanism not fully elucidated. Primarily inhibits cyclooxygenase (COX) enzymes in the central nervous system, possibly a COX-3 variant, reducing prostaglandin E2 synthesis and hypothalamic fever response. Weak peripheral COX-1/COX-2 inhibition. Additional actions include activation of descending serotonergic inhibitory pathways, transient receptor potential vanilloid 1 (TRPV1) modulation, and inhibition of fatty acid amide hydrolase (FAAH), enhancing endocannabinoid signaling.",
  "pharmacokinetics": {
    "absorption": "Rapidly absorbed from gastrointestinal tract; oral bioavailability 70-90%; onset of analgesia 15-60 minutes; peak plasma concentration 0.5-2 hours.",
    "metabolism": "Hepatic phase II conjugation predominant: glucuronidation (50-60%), sulfation (25-35%); minor CYP2E1, CYP1A2, CYP3A4 oxidation to N-acetyl-p-benzoquinone imine (NAPQI), detoxified by glutathione.",
    "elimination": "Primarily renal excretion of metabolites (90-100% within 24 hours); <5% excreted unchanged in urine.",
    "half_life": "1.5-3 hours in adults (prolonged to 4-8 hours in hepatic impairment or neonates)."
  },
  "clinical_use": {
    "approved_indications": [
      "Relief of mild to moderate pain",
      "Reduction of fever"
    ],
    "off_label_uses": [
      "Postoperative pain (intravenous formulation)",
      "Osteoarthritis pain",
      "Headache and migraine",
      "Dysmenorrhea"
    ],
    "standard_dosing": "Adults: 500-1000 mg orally or rectally every 4-6 hours as needed; maximum 4000 mg/day. Children (\u22652 years): 10-15 mg/kg/dose every 4-6 hours; maximum 75 mg/kg/day (not exceeding adult maximum).",
    "dose_adjustments": {
      "Renal impairment": "CrCl 10-50 mL/min: every 6 hours; CrCl <10 mL/min or hemodialysis: every 8 hours; maximum 3000 mg/day.",
      "Hepatic impairment": "Mild-moderate: maximum 3000 mg/day; severe (Child-Pugh C): avoid or maximum 2000 mg/day with close monitoring."
    }
  },
  "safety_profile": {
    "common_adverse_effects": [],
    "serious_adverse_effects": [],
    "contraindications": [],
    "black_box_warnings": []
  },
  "interactions": {
    "drug_interactions": [
      {
        "type": "drug-drug",
        "agent": "Ethanol (chronic heavy use)",
        "severity": "severe",
        "mechanism": "PK: Induction of CYP2E1, increasing toxic NAPQI metabolite formation",
        "clinical_effect": "Hepatotoxicity, potentially fulminant liver failure",
        "management": "Avoid concurrent use; if necessary, use minimal effective paracetamol dose and monitor LFTs closely",
        "time_separation": null,
        "evidence_level": "moderate"
      },
      {
        "type": "drug-drug",
        "agent": "Warfarin",
        "severity": "moderate",
        "mechanism": "PD/PK: Possible inhibition of warfarin metabolism or enhanced anticoagulant effect",
        "clinical_effect": "Elevated INR, increased bleeding risk",
        "management": "Monitor INR frequently, particularly with high-dose or prolonged paracetamol use",
        "time_separation": null,
        "evidence_level": "moderate"
      },
      {
        "type": "drug-drug",
        "agent": "Lamotrigine",
        "severity": "moderate",
        "mechanism": "PK: Paracetamol induces lamotrigine glucuronidation",
        "clinical_effect": "Decreased lamotrigine plasma concentrations, reduced efficacy",
        "management": "Monitor lamotrigine levels and clinical response; titrate dose as needed",
        "time_separation": null,
        "evidence_level": "moderate"
      },
      {
        "type": "drug-drug",
        "agent": "Probenecid",
        "severity": "moderate",
        "mechanism": "PK: Inhibits renal excretion and glucuronidation of paracetamol",
        "clinical_effect": "Increased paracetamol exposure, risk of toxicity",
        "management": "Monitor for hepatotoxicity; consider paracetamol dose reduction",
        "time_separation": null,
        "evidence_level": "moderate"
      },
      {
        "type": "drug-drug",
        "agent": "Isoniazid",
        "severity": "moderate",
        "mechanism": "PK/PD: Additive hepatotoxicity; possible CYP2E1 induction",
        "clinical_effect": "Elevated liver enzymes, hepatotoxicity",
        "management": "Monitor LFTs regularly",
        "time_separation": null,
        "evidence_level": "moderate"
      },
      {
        "type": "drug-drug",
        "agent": "Metoclopramide",
        "severity": "minor",
        "mechanism": "PK: Enhanced gastric emptying accelerates absorption",
        "clinical_effect": "Faster onset of action, no change in overall exposure",
        "management": "No dose adjustment required",
        "time_separation": null,
        "evidence_level": "moderate"
      },
      {
        "type": "drug-drug",
        "agent": "Cholestyramine",
        "severity": "minor",
        "mechanism": "PK: Physical binding in gastrointestinal tract",
        "clinical_effect": "Reduced paracetamol absorption if co-administered",
        "management": "Administer paracetamol at least 1 hour before or 4 hours after cholestyramine",
        "time_separation": "1 hour before or 4 hours after",
        "evidence_level": "moderate"
      },
      {
        "type": "drug-drug",
        "agent": "Activated charcoal",
        "severity": "minor",
        "mechanism": "PK: Adsorption in gastrointestinal tract",
        "clinical_effect": "Decreased paracetamol bioavailability",
        "management": "Separate administration by at least 1 hour",
        "time_separation": "1 hour",
        "evidence_level": "moderate"
      }
    ],
    "food_interactions": [],
    "environmental_considerations": []
  },
  "recommendations": {
    "evidence_based": [],
    "investigational": [],
    "debunked_claims": []
  },
  "monitoring": {
    "requirements": [],
    "warning_signs": []
  },
  "metadata": {
    "evidence_quality": "moderate",
    "analysis_confidence": 0.75,
    "reasoning_steps_count": 4
  },
  "cost_analysis": {
    "total_cost": 0.0042608,
    "total_duration": 199.989508,
    "phases": [
      {
        "phase": "Phase 1: Pharmacology Analysis",
        "cost": 0.00043840000000000003,
        "duration": 16.741352,
        "input_tokens": 832,
        "output_tokens": 544,
        "models_used": [
          "grok-4-1-fast-reasoning-latest"
        ]
      },
      {
        "phase": "Phase 2: Interaction Analysis",
        "cost": 0.0014759,
        "duration": 114.535113,
        "input_tokens": 1937,
        "output_tokens": 2177,
        "models_used": [
          "grok-4-1-fast-reasoning-latest"
        ]
      },
      {
        "phase": "Phase 3: Safety Profile Assessment",
        "cost": 0.0007383,
        "duration": 20.480859,
        "input_tokens": 469,
        "output_tokens": 1289,
        "models_used": [
          "grok-4-1-fast-reasoning-latest"
        ]
      },
      {
        "phase": "Phase 4: Recommendation Synthesis",
        "cost": 0.0011763000000000001,
        "duration": 31.576522,
        "input_tokens": 439,
        "output_tokens": 2177,
        "models_used": [
          "grok-4-1-fast-reasoning-latest"
        ]
      },
      {
        "phase": "Phase 5: Monitoring Requirements",
        "cost": 0.00043190000000000004,
        "duration": 16.655662,
        "input_tokens": 327,
        "output_tokens": 733,
        "models_used": [
          "grok-4-1-fast-reasoning-latest"
        ]
      }
    ],
    "most_expensive": [
      {
        "phase": "Phase 2: Interaction Analysis",
        "cost": 0.0014759,
        "duration": 114.535113,
        "input_tokens": 1937,
        "output_tokens": 2177,
        "models_used": [
          "grok-4-1-fast-reasoning-latest"
        ]
      },
      {
        "phase": "Phase 4: Recommendation Synthesis",
        "cost": 0.0011763000000000001,
        "duration": 31.576522,
        "input_tokens": 439,
        "output_tokens": 2177,
        "models_used": [
          "grok-4-1-fast-reasoning-latest"
        ]
      },
      {
        "phase": "Phase 3: Safety Profile Assessment",
        "cost": 0.0007383,
        "duration": 20.480859,
        "input_tokens": 469,
        "output_tokens": 1289,
        "models_used": [
          "grok-4-1-fast-reasoning-latest"
        ]
      }
    ]
  }
}